Luye Pharma Group Ltd. (HKG:2186)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.880
+0.090 (2.37%)
Sep 8, 2025, 4:08 PM HKT
2.37%
Market Cap15.09B
Revenue (ttm)6.76B
Net Income (ttm)434.95M
Shares Out3.89B
EPS (ttm)0.12
PE Ratio33.56
Forward PE19.64
Dividendn/a
Ex-Dividend Daten/a
Volume106,949,500
Average Volume76,435,413
Open3.810
Previous Close3.790
Day's Range3.770 - 3.940
52-Week Range1.670 - 4.490
Beta0.82
RSI54.96
Earnings DateAug 28, 2025

About Luye Pharma Group

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surg... [Read more]

Sector Healthcare
Founded 1994
Employees 5,150
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2186
Full Company Profile

Financial Performance

In 2024, Luye Pharma Group's revenue was 6.06 billion, a decrease of -1.33% compared to the previous year's 6.14 billion. Earnings were 471.89 million, a decrease of -11.40%.

Financial numbers in CNY Financial Statements

News

RRJ Buys $150 Million Luye Bonds, First China Deal Since 2019

RRJ Capital, founded by former Goldman Sachs Group Inc. banker Richard Ong, will fully subscribe to the $150 million convertible bonds issued by Luye Pharma Group Ltd., marking its first investment in...

11 months ago - BNN Bloomberg